Analyst Color - Spark Newswire

1 minute read

Why Credit Suisse Is Bullish On Boston Beer Company

Today, 10:06 AM

A combination of reopenings and seltzer market growth has Credit Suisse bullish on Boston Beer Company, Inc (NYSE: SAM). The Boston Beer Co. Analyst: Credit Suisse upgraded Boston Beer Co. from Neutral to Outperform and increased the price target from $1,304 to $1,490.

SAM

2 minute read

Alibaba’s Position In E-Commerce, Cloud Stronger Than Feared By Wall Street, Says Analyst

By Rachit Vats

Today, 10:06 AM

Alibaba Group Holding (NYSE: BABA)’s position in e-commerce and cloud markets after it paid up a record $2.8 billion antitrust fine is better-than-feared, according to KeyBanc Capital Markets.

AMZN

1 minute read

Warren Buffett-Backed Automaker BYD Could Fully Transition To NEVs As Evident From Sale-Numbers, Say Analysts

By Rachit Vats

Today, 10:06 AM

Chinese legacy automaker BYD Co Ltd (OTC: BYDDF) could transition to a fully new-energy-vehicle portfolio, a Huaxi Securities analyst said, as reported by c

BRK-A

1 minute read

Arrowhead’s Big Sell-Off Presents Buying Opportunity, According to HC Wainwright

By Nikhil Dayal

Today, 10:06 AM

The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.

ARWR

2 minute read

Unprofitable Companies Are Flooding The Market With Stock Offerings: What Does It Mean?

By Wayne Duggan

Today, 10:06 AM

AMC Entertainment Holdings Inc (NYSE: AMC) and GameStop Corp.

AMC

1 minute read

Takeaways On Unity Biotech’s Clinical Data From A Bull Analyst

By Nikhil Dayal

Today, 10:06 AM

Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX). The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target.

UBX

1 minute read

Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity

By Nikhil Dayal

Today, 10:06 AM

The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: ABUS). The Arbutus Analyst: Ed Arce raffirmed a Buy rating on shares of Arbutus Biopharma Corp. with a $10 price target.

ABUS

2 minute read

What We Know About Apple’s Next iPhone

By Shanthi Rexaline

Today, 10:06 AM

Apple, Inc.'s (NASDAQ: AAPL) hardware releases, especially the release of its flagship product, the iPhone, are always watched keenly. And rightfully so: the iPhone fetches over half of the company's total revenues.

AAPL

1 minute read

Why This ChemoCentryx Analyst Is Bullish

By Nikhil Dayal

Today, 10:06 AM

H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on shares of ChemoCentryx, Inc. with a $28 price target.

CCXI

2 minute read

Why Zeta Global’s Proprietary Customer Database Has BofA Bullish

By Nikhil Dayal

Today, 10:06 AM

A differentiated proprietary customer database has turned a BofA Securities analyst bullish on shares of Zeta Global Corp (NYSE: ZETA). The Zeta Analyst: Koji Ikeda initiated coverage on shares of Zeta Global Corp. with a Buy rating and $12 price target.

ZETA